IMG 7289

Drug Profile

IMG 7289

Alternative Names: IMG-7289; LSD1 inhibitor - Imago BioSciences

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Imago BioSciences
  • Class Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Myeloproliferative disorders

Most Recent Events

  • 10 Oct 2016 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Late-stage disease, Monotherapy) in Australia (PO)
  • 10 Oct 2016 Phase-I clinical trials in Myelodysplastic syndromes (Combination therapy, Late-stage disease, Monotherapy) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top